$CRSP
CRISPR Therapeutics AG

2017 Q2 Form 10-Q Financial Statement

#000119312517254536 Filed on August 10, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2016 Q4 2016 Q2
Revenue $3.582M $2.300M $795.0K
YoY Change 350.57% 831.17%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.800M $12.10M $8.800M
YoY Change -11.36% 95.16% 319.05%
% of Gross Profit
Research & Development $17.12M $15.60M $8.602M
YoY Change 99.02% 151.61% 473.47%
% of Gross Profit
Depreciation & Amortization $700.0K $420.0K $100.0K
YoY Change 600.0% 600.0% 400.0%
% of Gross Profit
Operating Expenses $24.89M $27.70M $17.35M
YoY Change 43.42% 123.15% 378.7%
Operating Profit -$21.31M -$16.56M
YoY Change 28.67% 356.77%
Interest Expense -$500.0K -$35.80M -$700.0K
YoY Change -28.57% 35700.0%
% of Operating Profit
Other Income/Expense, Net -$666.0K $78.70M -$606.0K
YoY Change 9.9%
Pretax Income -$21.97M $17.50M -$17.16M
YoY Change 28.01% -243.44% 376.78%
Income Tax $343.0K $400.0K $0.00
% Of Pretax Income 2.29%
Net Earnings -$22.32M $17.10M -$17.16M
YoY Change 30.06% -239.36% 370.96%
Net Earnings / Revenue -622.98% 743.43% -2158.11%
Basic Earnings Per Share -$0.56 $0.43
Diluted Earnings Per Share -$0.56 $0.40 -$433.2K
COMMON SHARES
Basic Shares Outstanding 39.90M 32.99M
Diluted Shares Outstanding 39.90M 34.99M

Balance Sheet

Concept 2017 Q2 2016 Q4 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $272.3M $315.5M $246.8M
YoY Change 10.33% 102.24%
Cash & Equivalents $272.3M $315.5M $246.8M
Short-Term Investments
Other Short-Term Assets $2.200M $1.500M $1.000M
YoY Change 120.0% 200.0%
Inventory
Prepaid Expenses
Receivables $6.814M $3.157M $1.400M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $281.3M $320.2M $249.2M
YoY Change 12.88% 104.15%
LONG-TERM ASSETS
Property, Plant & Equipment $19.93M $21.03M $2.400M
YoY Change 730.29% 1483.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $36.50M $35.70M
YoY Change -100.0%
Other Assets $237.0K $198.0K $5.400M
YoY Change -95.61% 96.04%
Total Long-Term Assets $23.69M $24.77M $43.90M
YoY Change -46.04% 859.12%
TOTAL ASSETS
Total Short-Term Assets $281.3M $320.2M $249.2M
Total Long-Term Assets $23.69M $24.77M $43.90M
Total Assets $305.0M $345.0M $293.1M
YoY Change 4.05% 116.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.559M $4.569M $3.700M
YoY Change -30.84% 188.45%
Accrued Expenses $11.89M $16.32M $13.20M
YoY Change -9.94% 93.59%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.81M $22.00M $80.60M
YoY Change -80.38% 116.62%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $198.0K $189.0K $77.10M
YoY Change -99.74% -32.74%
Total Long-Term Liabilities $198.0K $189.0K $77.10M
YoY Change -99.74% -32.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.81M $22.00M $80.60M
Total Long-Term Liabilities $198.0K $189.0K $77.10M
Total Liabilities $107.2M $112.1M $157.7M
YoY Change -32.04% -9.6%
SHAREHOLDERS EQUITY
Retained Earnings -$100.9M -$57.08M
YoY Change 68.36%
Common Stock $298.7M $290.0M
YoY Change 5919.41%
Preferred Stock
YoY Change
Treasury Stock (at cost) $0.00 $0.00
YoY Change
Treasury Stock Shares 444.9K shares $0.00
Shareholders Equity $197.8M $232.8M $135.4M
YoY Change
Total Liabilities & Shareholders Equity $305.0M $345.0M $293.1M
YoY Change 4.05% 116.38%

Cashflow Statement

Concept 2017 Q2 2016 Q4 2016 Q2
OPERATING ACTIVITIES
Net Income -$22.32M $17.10M -$17.16M
YoY Change 30.06% -239.36% 370.96%
Depreciation, Depletion And Amortization $700.0K $420.0K $100.0K
YoY Change 600.0% 600.0% 400.0%
Cash From Operating Activities -$15.97M -$19.42M -$13.61M
YoY Change 17.34% -128.14% 407.84%
INVESTING ACTIVITIES
Capital Expenditures -$1.330M -$230.0K -$1.050M
YoY Change 26.67% -54.0% 950.0%
Acquisitions
YoY Change
Other Investing Activities $15.00M $0.00
YoY Change
Cash From Investing Activities -$1.330M $14.77M -$1.050M
YoY Change 26.67% -3054.0% 950.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $35.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 700.0K 91.77M 60.93M
YoY Change -98.85% 138.49% 15.05%
NET CHANGE
Cash From Operating Activities -15.97M -19.42M -13.61M
Cash From Investing Activities -1.330M 14.77M -1.050M
Cash From Financing Activities 700.0K 91.77M 60.93M
Net Change In Cash -16.60M 87.12M 46.27M
YoY Change -135.88% -18.57% -7.79%
FREE CASH FLOW
Cash From Operating Activities -$15.97M -$19.42M -$13.61M
Capital Expenditures -$1.330M -$230.0K -$1.050M
Free Cash Flow -$14.64M -$19.19M -$12.56M
YoY Change 16.56% -127.61% 386.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
40591669 shares
CY2017Q2 us-gaap Treasury Stock Value
TreasuryStockValue
0
CY2017Q2 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1561000
CY2017Q2 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
1255000
CY2017Q2 crsp Prepaid Expense And Other Assets Related Parties Current
PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent
1141000
CY2017Q2 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
2663000
CY2017Q2 crsp Accrued Expenses Related Parties Current
AccruedExpensesRelatedPartiesCurrent
305000
CY2017Q2 crsp Deferred Revenue Related Parties Noncurrent
DeferredRevenueRelatedPartiesNoncurrent
284000
CY2017Q2 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
783000
CY2017Q2 crsp Common Stock Conditional Capital
CommonStockConditionalCapital
17079353 shares
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
246849000
CY2017Q2 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
1340000
CY2017Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11888000
CY2017Q2 us-gaap Assets Current
AssetsCurrent
281285000
CY2017Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6814000
CY2017Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1892000
CY2017Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2340000
CY2017Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
297446000
CY2017Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2559000
CY2017Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000
CY2017Q2 us-gaap Assets
Assets
304975000
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
272264000
CY2017Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40556891 shares
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40039415 shares
CY2017Q2 us-gaap Cash
Cash
272264000
CY2017Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
17079353 shares
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40484288 shares
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
1226000
CY2017Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
11928000
CY2017Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
1027000
CY2017Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
79232000
CY2017Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3567000
CY2017Q2 us-gaap Equity Method Investments
EquityMethodInvestments
0
CY2017Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
35700000
CY2017Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
372000
CY2017Q2 us-gaap Liabilities
Liabilities
107172000
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
304975000
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
15814000
CY2017Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
167000
CY2017Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
68000
CY2017Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
237000
CY2017Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
198000
CY2017Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2207000
CY2017Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19927000
CY2017Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
22267000
CY2017Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3154000
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-100873000
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
197803000
CY2017Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
272000
CY2017Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
444873 shares
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
155961000
CY2016Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
752000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16320000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
320188000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3157000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2715000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
942000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
288739000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4569000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-26000
CY2016Q4 us-gaap Assets
Assets
344962000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
315520000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40253674 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39719434 shares
CY2016Q4 us-gaap Cash
Cash
315520000
CY2016Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
15325607 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40164307 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
1216000
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
12283000
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
1027000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
77646000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2585000
CY2016Q4 us-gaap Equity Method Investments
EquityMethodInvestments
0
CY2016Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
399000
CY2016Q4 us-gaap Liabilities
Liabilities
112116000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
344962000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21998000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1079000
CY2016Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
59000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
198000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
189000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1511000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21027000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21969000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3150000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57083000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
232846000
CY2016Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
23000
CY2016Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
444873 shares
CY2016Q4 us-gaap Treasury Stock Value
TreasuryStockValue
0
CY2017Q2 us-gaap Revenues
Revenues
3582000
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39895938 shares
CY2016Q4 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
996000
CY2016Q4 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
3372000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Type
DocumentType
10-Q
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.10
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0144 pure
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M12D
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2016Q4 crsp Prepaid Expense And Other Assets Related Parties Current
PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent
0
CY2016Q4 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
5081000
CY2016Q4 crsp Accrued Expenses Related Parties Current
AccruedExpensesRelatedPartiesCurrent
537000
CY2016Q4 crsp Deferred Revenue Related Parties Noncurrent
DeferredRevenueRelatedPartiesNoncurrent
527000
CY2016Q4 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
492000
CY2016Q4 crsp Common Stock Conditional Capital
CommonStockConditionalCapital
15325607 shares
dei Amendment Flag
AmendmentFlag
false
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7977000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5709389000 shares
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2697000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-43256000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43760000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Depreciation
Depreciation
1400000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1426000
dei Document Period End Date
DocumentPeriodEndDate
2017-06-30
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
31000
dei Entity Registrant Name
EntityRegistrantName
CRISPR THERAPEUTICS AG
dei Entity Central Index Key
EntityCentralIndexKey
0001674416
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
30000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-167000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4615000
us-gaap Operating Expenses
OperatingExpenses
48335000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
715000
us-gaap Net Income Loss
NetIncomeLoss
-43790000
us-gaap Operating Income Loss
OperatingIncomeLoss
-42050000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1118000
us-gaap Profit Loss
ProfitLoss
-43790000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2013-10-28
dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Basel, Switzerland
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
9000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16410000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43168000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1586000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2103000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3657000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
278000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-951000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
622000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
736000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
4000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-4615000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-39387000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
715000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31925000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
2639000
us-gaap Revenues
Revenues
6285000
us-gaap Share Based Compensation
ShareBasedCompensation
7026000
dei Trading Symbol
TradingSymbol
CRSP
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39811412 shares
crsp Cost Sharing Expenses Incurred
CostSharingExpensesIncurred
1000000
crsp Cost Sharing Expenses Accrued
CostSharingExpensesAccrued
800000
crsp Research And Development Expense From Related Party
ResearchAndDevelopmentExpenseFromRelatedParty
2491000
crsp Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
-355000
crsp Joint Venture Agreement Date
JointVentureAgreementDate
2015-12-19
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4523000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
47000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
90888000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25623000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
61929000
us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
277000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.66
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0030 pure
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-40000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-14000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-28000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
11482000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14867000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25530000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
710000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4988000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1015000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
51000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-686000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
76000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2573000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
2453000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-8050000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
18621000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-23618000
us-gaap Operating Expenses
OperatingExpenses
29481000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
95925000
us-gaap Net Income Loss
NetIncomeLoss
-25596000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-10000
us-gaap Operating Income Loss
OperatingIncomeLoss
-28210000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2680000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-17000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-66000
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
100000
us-gaap Paid In Kind Interest
PaidInKindInterest
8050000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1279000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
35000000
us-gaap Profit Loss
ProfitLoss
-25606000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14614000
us-gaap Revenues
Revenues
1271000
us-gaap Share Based Compensation
ShareBasedCompensation
4523000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5488467 shares
crsp Issuance Costs For Initial Public Offering In Accounts Payable And Accrued Expenses
IssuanceCostsForInitialPublicOfferingInAccountsPayableAndAccruedExpenses
1810000
crsp Proceeds From Contribution Of Intellectual Property To Equity Method Investee
ProceedsFromContributionOfIntellectualPropertyToEquityMethodInvestee
20000000
crsp Noncash Contribution Of Intellectual Property To Equity Method Investee
NoncashContributionOfIntellectualPropertyToEquityMethodInvestee
36372000
crsp Cost Sharing Expenses Incurred
CostSharingExpensesIncurred
800000
crsp Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
184000
CY2017Q2 crsp Number Of Options Approved To Be Granted
NumberOfOptionsApprovedToBeGranted
2012684 shares
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4624738000 shares
CY2016 crsp Cost Sharing Expenses Accrued
CostSharingExpensesAccrued
2800000
CY2016Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3501000
CY2016Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17177000
CY2016Q2 us-gaap Depreciation
Depreciation
100000
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.15
CY2016Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000 pure
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8751000
CY2016Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17164000
CY2016Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-686000
CY2016Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
17353000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-17157000
CY2016Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-7000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-16558000
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-606000
CY2016Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-13000
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
80000
CY2016Q2 us-gaap Profit Loss
ProfitLoss
-17164000
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8602000
CY2016Q2 us-gaap Revenues
Revenues
795000
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5448855 shares
CY2016Q2 crsp Cost Sharing Expenses Incurred
CostSharingExpensesIncurred
300000
CY2017Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4231000
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22309000
CY2017Q2 us-gaap Depreciation
Depreciation
700000
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.56
CY2017Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0160 pure
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7768000
CY2017Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21972000
CY2017Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-505000
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
343000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
24888000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-22315000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-21306000
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-666000
CY2017Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
6000
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-161000
CY2017Q2 us-gaap Profit Loss
ProfitLoss
-22315000
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17120000
CY2017Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1475000
CY2017Q2 crsp Cost Sharing Expenses Incurred
CostSharingExpensesIncurred
500000
CY2017Q2 crsp Research And Development Expense From Related Party
ResearchAndDevelopmentExpenseFromRelatedParty
1355000

Files In Submission

Name View Source Status
0001193125-17-254536-index-headers.html Edgar Link pending
0001193125-17-254536-index.html Edgar Link pending
0001193125-17-254536.txt Edgar Link pending
0001193125-17-254536-xbrl.zip Edgar Link pending
crsp-20170630.xml Edgar Link completed
crsp-20170630.xsd Edgar Link pending
crsp-20170630_cal.xml Edgar Link unprocessable
crsp-20170630_def.xml Edgar Link unprocessable
crsp-20170630_lab.xml Edgar Link unprocessable
crsp-20170630_pre.xml Edgar Link unprocessable
d414775d10q.htm Edgar Link pending
d414775dex311.htm Edgar Link pending
d414775dex312.htm Edgar Link pending
d414775dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending